Ryzneuta Side Effects

Generic name: efbemalenograstim alfa

Medically reviewed by Drugs.com. Last updated on Sep 10, 2024.

Note: This document provides detailed information about Ryzneuta.

Applies to efbemalenograstim alfa: parenteral injection for sub-q use Side Effects associated with efbemalenograstim alfa. Some dosage forms listed on this page may not apply specifically to the brand name Ryzneuta.

Applies to efbemalenograstim alfa: parenteral injection for sub-q use.

Side effects include:

Adverse effects reported in ≥10% of patients receiving efbemelanograstim alfa-vuxw include nausea, anemia, and thrombocytopenia.

For healthcare professionals

Applies to efbemalenograstim alfa: subcutaneous solution.

General adverse events

The most common adverse reactions with a frequency of 10% or greater were nausea, anemia, thrombocytopenia, fatigue, and bone pain.^[Ref]

Cardiovascular

• Frequency not reported: Capillary leak syndrome, aortitis

Hematologic

• Very common (10% or more): Anemia (up to 12%), thrombocytopenia (up to 10%)
• Frequency not reported: Sickle cell crisis, leukocytosis

Hypersensitivity

• Frequency not reported: Serious allergic reactions

Oncologic

• Frequency not reported: Myelodysplastic syndrome, acute myeloid leukemia

Other

• Frequency not reported: Splenic rupture

Respiratory

• Frequency not reported: Acute respiratory distress syndrome

Genitourinary

• Very common (10% or more): Nausea (up to 42%)

Renal

• Frequency not reported: Glomerulonephritis

Further information

Ryzneuta side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer